Tag Archives | Ovum

[GUEST POST] Informa adds IHS Markit tech analysts to equal Forrester

IHS Informa logos (IIAR website)Informa (INF.L) has acquired IHS Markit’s (INFO) TMT business. Informa Tech, which includes Ovum, will have revenues similar to Forrester’s $350m. It represents a dramatic shift in the analyst landscape.

Informa announced the transaction on 22 May as part of an exchange of Informa’s agribusiness service for IHS Markit’s TMT portfolio, including the OTT and media teams.

A sixty-year-old firm built through acquisitions, IHS its has absorbed numerous tech research firms, including Infonetics Research and IMS Research.

IHS Markit has clarified that it will retain RootMetrics and part of its market intelligence business. Because the exchange is subject to US regulatory approval, it can’t be completed until July at the earliest.

Continue Reading →

Continue Reading

IIAR Analyst Of The Year 2018 – The Awards Unwrapped.

Who’d have thought Christmas would come this early? Grab a glass of bubbles, put on the festive music and light the fire. It’s time to unveil the IIAR Analyst Of The Year award winners.

2018 was a year in which influencer relations became more important in delivering business impact, and so unsurprisingly analysts’ voices have been a critical focus for sales enablement and marketing. We see analysts themselves continuing to build profile beyond repors, through social media and content, and in response organisations are ramping their commitment to tracking how analysts impact their brand. It’s an exciting, evolving time.

So for the IIAR community, it’s important to recognise the range of analysts and firms who are leading the way. We listen carefully to the voices of our members and remain fully engaged with the global analyst network.

To this end we’ve heard from the community in eleven countries across four continents. We’ve reviewed hundreds of nominations and thousands of point scores. Award winners were determined based on the scoring provided by IIAR members, in accordance with the IIAR SOSM methodology. The nominations therefore reflect the best practice promoted within the IIAR.

All of this leads to one thing – as a festive drumroll is unleashed – the award winners Continue Reading →

Continue Reading

In memory of Brian Riggs

We were very sad and shocked to hear the news that Brian Riggs of Ovum and No Jitter died this weekend in a swimming accident.

He was truly one of the best, and the analyst world is poorer without him.

Dave Michels of TalkingPointz has written a very lovely post about Brian which is very much worth reading if you knew him.

Our condolences go to his family, friends and colleagues. Rest in peace Sir.

Continue Reading

What’s really going on with Ovum? Meet the MD, Aneil Rakity

Aneil Rakity / Ovum - IIAR website - Photo©John Cassidy The Headshot Guy® www.theheadshotguy.co.uk 07768 401009Ovum (related blog posts, website) the UK-based analyst firm which enjoys a soft spot in the hearts of many AR pros, has gone through tough times in recent years.

Multiple changes of ownership accompanied by several different MDs have led to inconsistent and regularly changing strategies for the business, and a considerable turnover of staff.

Is this period in Ovum’s history now at an end, following the appointment of Aneil Rakity (LinkedIn) as the MD in 2016?

David Rossiter (LinkedIn, @davidrossiter), IIAR UK Chapter and director of analyst relations at Harvard, had the opportunity recently to sit down with Aneil and chief research officer Tim Jennings (@tjennings, LinkedIn) to find out what’s going on.

Read on for this and don’t miss the IIAR Webinar with Ovum on Wednesday 25th October > REGISTER NOW.

Continue Reading →

Continue Reading

IIAR Webinar & Cafe with Ovum POSTPONED

PLEASE NOTE THAT UNFORTUNATELY WE HAVE TO POSTPONE THIS SESSION,  apologies for any inconvenience caused

There are lots of rumours on what is going on at Ovum. David Rossiter, Sunesis Global AR (LinkedIn, @davidrossiter), will be hosting an IIAR Cafe with the MD and Chief Research Officer, providing you with the perfect opportunity to come meet with and learn what is really going on.

Aneil Rakity, managing director(LinkedIN)and Tim Jennings, chief research officer, (LinkedIN, @tjennings) will be sharing the truth about what’s happening at Ovum and putting to bed some of the rumours that have been flying around about the company for the past couple of years, including the future of the brand. The presentation and open Q&A session will include updates on Ovum’s strategy, market positioning, target markets and competitive differentiators as well as the latest on its research organisation and research agenda. They’ll also be talking about how Ovum fits within Informa, the big investments taking place in product development, its expansion into the US market and the continuing convergence between Ovum’s service provider and technology teams.

If you’re interested in Ovum, this is a “don’t miss” event. Pre-registration is essential

David Rossiter

Date: TO BE CONFIRMED
Time: TO BE CONFIRMED
Location: London & Webinar

 

Note that this event is open to IIAR members, the Forum is free to attend for IIAR Members (another good reason for joining the IIAR) or for non-members there is a fee of £75 that is redeemable against IIAR Membership over the next 12 months. Click here to proceed.

 or 

 

Continue Reading

The IIAR Tragic Quadrant for 2017

Two years ago, in 2015, we produced the first IIAR Tragic Quadrant. It was met with much enthusiasm and comment, thus we have decided to repeat the exercise once again this year. Below we present the Tragic Quadrant for 2017. The Tragic Quadrant is compiled from data collected as part of the 2016 IIAR Analyst of the Year Survey, where, annually, we invite analyst relations professionals to rate individual industry analyst and the firms they work for. This year more than 100 different individual organisations responded to our survey. We were interested to see if we could do further analysis on the data that was collected.

In producing the Tragic Quadrant what we sought to do was to rank analyst firms according to three criteria. We chose these criteria because this is what the IIAR survey asks respondents to assess:

  • Impact: The Y axis depicts the ‘Impact’ of the industry analyst firm on the purchase decision. This also relates to their perceived credibility and capability to provide an objective opinion.
  • Relevance: The X axis marks their ‘Relevance’ for the purchase decision. This means their capability to cover the market and their specific geographical allocation. It also includes public recognition of their presence in the market (e.g. as an expert).
  • Interaction: The size of the bubble is ‘Interaction’. This relates to issues of communication (e.g. how easy is it to get to them and to talk to them).

Continue Reading →

Continue Reading

Around Tim Jennings from Ovum in 10 questions

Today we ask our probing questions of Tim Jennings (LinkedIn, @tjennings, bio) Chief Research Officer and Research Fellow at Ovum (@ovum, see related posts).

 

1. What are your coverage areas?Ovum Tim Jennings
As Chief Research Officer at Ovum, my focus is less on a specific topic, and more on how technology overall is being applied to create business value. That said, I need to keep abreast of all the hot topics, and be able to hold vaguely sensible conversations on anything from converged infrastructure to customer experience. If I was to pick the coverage area that I enjoy most, it would be BI and information management.

Continue Reading →

Continue Reading

IIAR members – be among the first to meet the management team of new Ovum

Ovum logoAt 17:00 on the 26th June, the UK arm of the IIAR is meeting with Steve Hotham CEO of the newly merged Ovum / ITM Research company (which is branded Ovum), along with Martin Hill, MD of Ovum’s Telecoms Research and Consulting, and Ian Charlesworth, MD of Ovum’s IT Research and Consulting.

They will be presenting the new Ovum organisation and its new product range and capabilities as well as explaining the many changes that have taken place as a result of the merger, which was announced in April. Continue Reading →

Continue Reading

[GUEST POST] This Thursday, learn what the new Ovum is up to: webinar with CEO Steve Hotham

By David Rossiter (LinkedIn@davidrossiter) from Sunesis,

The new CEO at OvumSteve Hotham, is hosting a webinar on Thursday this week (May 22nd 2014) at 1600 UK time.

It’s open to all AR professionals and users of the current Ovum and Informa Telecoms & Media (ITM) research services.

According to Claire Booty, PR manager for Ovum, Steve will use the webinar to explain the rationale behind the merger of Ovum and ITM, highlight its new products, research agenda, and introduce key staff appointments.

If you want to attend, just email Claire with the names, job roles and contact details of those who wish to attend. She’ll send you all the details.

 

 

About the author

David Rossiter (LinkedIn@davidrossiter) runs Sunesis, a specialist AR agency, and writes the Analyst Insight blog.  He is a former board member of the IIAR and is now co-chair of the UK chapter.

Continue Reading

Ovum finally gets assimilated

ovum[1]It’s been quite a long time in the making, it follows many acquisition rumours, many merger denials, but it’s finally there: Ovum merges with Informa Telecom and Media.

On paper, it’s the fourth ICT analysis firm of the market, depending on where place the line between analysis and market research. The staff doesn’t change much and they’re keeping the stronger brand, Ovum.

The merged business, which will be fully integrated by the end of May, will be led by Steve Hotham, current MD of Ovum, who will become its CEO. Spread across 23 offices, in 6 continents, Ovum will employ 275 staff, including 180 analysts providing a combination of global and local insight.

The press release doesn’t menti0n end-user influence, a key difference between both firms, but the Ovum Industry Congress is coming soon and will be a good place to assess this.

 

There are few reasons to change my conclusions from a previous post:

  • Ovum remains a credible analyst firm in its key markets, so AR folks should not discount it

  • AR pros should look for opportunities to leverage this 180-analysts strong firm, while watching for coverage gaps

  • AR pros should consider Ovum’s vertical technology expertise when creating vertical AR plans/programmes as it’s part of its DNA AR pros should check vertical coverage outside of telco
  • Like many other research firms, Ovum needs to more clearly articulate its differentiation and generate market awareness via sharper thought leadership

 

Older posts on Ovum: